|
PCV serotypes
|
Hospitalization rates per 100,000 person-years
|
Relative difference in hospitalization rates
|
|---|
|
2009
|
2011
|
2012
|
2009 to 2011
|
2009 to 2012
|
|---|
|
Rate (95 % CI)
|
Rate (95 % CI)
|
Rate (95 % CI)
|
% (95 % CI)
|
p
|
% (95 % CI)
|
p
|
|---|
|
Any lytA-positive (SARI program)
|
|
PCV-7
|
125.1 (93.7–163.6)
|
23.9 (11.9–42.8)
|
45.2 (28.0–69.1)
|
−80.9 (−90.9 to −62.9)
|
<0.001
|
−63.8 (−79.3 to −39.1)
|
<0.001
|
|
PCV-13
|
37.8 (21.6–61.3)
|
15.2 (6.1–31.3)
|
34.4 (19.7–55.9)
|
−59.7 (−85.9 to +3.4)
|
0.067
|
+8.8 (−94.8 to +57.3)
|
0.796
|
|
NVT
|
273.7 (226.2–328.3)
|
47.8 (30.0–72.4)
|
77.5 (54.3–107.3)
|
− 82.5 (−89.4 to −72.3)
|
<0.001
|
−71.7 (−81.1 to −58.5)
|
<0.001
|
|
All
|
436.6 (375.9–504.2)
|
86.9 (62.1–118.3)
|
157.1 (123.2–197.6)
|
−80.1 (−86.2 to −71.8)
|
<0.001
|
−64.0 (−72.9 to −52.6)
|
<0.001
|
|
Culture-positive (GERMS program)
|
|
PCV-7
|
77.9 (53.6–109.3)
|
13.0 (4.8–28.4)
|
6.5 (1.3–18.9)
|
−83.2 (−94.2 to – 59.5)
|
<0.001
|
−91.7 (−98.4 to −73.6)
|
<0.001
|
|
PCV-13
|
23.6 (11.3–43.4)
|
17.4 (7.5–34.2)
|
8.6 (2.3–22.1)
|
−26.3 (−74.7 to +107.3)
|
0.529
|
−63.5 (−91.6 to +26.5)
|
0.084
|
|
NVT
|
28.3 (14.6–49.5)
|
28.2 (15.0–48.3)
|
28.0 (14.9–47.8)
|
−0.2 (−58.0 to +139.2)
|
0.993
|
+1.2 (−96.7 to +58.4)
|
0.974
|
|
All
|
129.8 (97.8–168.9)
|
58.6 (38.7–85.3)
|
43.1 (26.3–66.5)
|
−54.8 (−72.6 to −27.1)
|
<0.001
|
−66.8 (−81.2 to −43.8)
|
<0.001
|
- Abbreviations: PCV-7: 7-valent pneumococcal conjugate vaccine serotypes (included serotypes/serogroups 4, 6A/B, 9A/V/L/N, 14, 18A/B/C, 19B/F, 23 F for lyA-positive samples and 4, 6A/B, 9 V, 14, 18C, 19 F, 23 F for culture-positive samples); PCV-13: additional 13-valent pneumococcal conjugate vaccine serotypes (included serotypes/serogroups 1, 3, 5, 7A/F, 19A for lyA-positive samples and 1, 3, 5, 7 F, 19A for culture-positive samples); NVT: serotypes/serogroups not included in PCV-7 or PCV-13, including samples that tested negative for the 42 serotypes detected by the serotyping assay for lytA-positive samples
